Do No Harm: Lymphedema Risk Reduction Behaviors [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Nudelman Tags: CORRESPONDENCE Source Type: research
LYMPHA: New Innovation, Not Old Practice [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Gomberawalla, Feldman Tags: CORRESPONDENCE Source Type: research
Reply to F. Felix et al and M.F. Fay et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Happold, Gorlia, Chinot, Gilbert, Nabors, Wick, Pugh, Hegi, Cloughesy, Roth, Reardon, Perry, Mehta, Stupp, Weller Tags: CORRESPONDENCE Source Type: research
Valproate in Adjuvant Glioblastoma Treatment [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Fay, Head, Sminia, Dowson, Cosgrove, Rose, Martin Tags: CORRESPONDENCE Source Type: research
Valproic Acid May Be Tested in Patients With H3F3A-Mutated High-Grade Gliomas [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Felix, Fontenele Tags: CORRESPONDENCE Source Type: research
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline [ASCO SPECIAL ARTICLE]
Purpose
To develop recommendations about endocrine therapy for women with hormone receptor (HR) –positive metastatic breast cancer (MBC).
Methods
The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC.
Recommendat...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Rugo, Rumble, Macrae, Barton, Connolly, Dickler, Fallowfield, Fowble, Ingle, Jahanzeb, Johnston, Korde, Khatcheressian, Mehta, Muss, Burstein Tags: Epidemiology, Chemotherapy, Combined Modality, Hormonal Therapy, ASCO Guidelines ASCO SPECIAL ARTICLE Source Type: research
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study [Gynecologic Cancer]
Conclusion
MMR defects in EECs are associated with a number of well-established poor prognostic indicators. Women with tumors that had MMR defects were likely to have higher-grade cancers and more frequent lymphovascular space invasion. Surprisingly, outcomes in these patients were similar to patients with MMR normal tumors, suggesting that MMR defects may counteract the effects of negative prognostic factors. Altered immune surveillance of MMR-deficient tumors, and other host/tumor interactions, is likely to determine outcomes for patients with MMR-deficient tumors. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: McMeekin, Tritchler, Cohn, Mutch, Lankes, Geller, Powell, Backes, Landrum, Zaino, Broaddus, Ramirez, Gao, Ali, Darcy, Pearl, DiSilvestro, Lele, Goodfellow Tags: Epidemiology, Diagnosis & Staging Gynecologic Cancer Source Type: research
Characteristics of Patients Who Survived 2 Years After Surgery for Spinal Metastases: Can We Avoid Inappropriate Patient Selection? [Surgical Oncology]
Conclusion
Poor performance status at presentation is the strongest indicator of poor short-term survival, whereas low disease load and favorable tumor histology are associated with longer-term survival. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Verlaan, Choi, Versteeg, Albert, Arts, Balabaud, Bunger, Buchowski, Chung, Coppes, Crockard, Depreitere, Fehlings, Harrop, Kawahara, Kim, Lee, Leung, Liu, Martin-Benlloch, Massicotte, Mazel, Meyer, Peul, Quraishi, Tokuhashi, Tomita, Ulbricht, Wang, Oner Tags: Prognostic Studies, Palliative Care, Surgical Oncology Source Type: research
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) [Gastrointestinal Cancer]
Conclusion
ColDx is associated with RFI in the C9581 subsample in the presence of other prognostic factors, including MMR deficiency. ColDx could be incorporated with the traditional clinical markers of risk to refine patient prognosis. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Niedzwiecki, Frankel, Venook, Ye, Friedman, Goldberg, Mayer, Colacchio, Mulligan, Davison, OBrien, Kerr, Johnston, Kennedy, Harkin, Schilsky, Bertagnolli, Warren, Innocenti Tags: Translational Oncology, Gastrointestinal, Gene Expression and Profiling Gastrointestinal Cancer Source Type: research
DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics [Gastrointestinal Cancer]
Conclusion
dMMR rectal cancer had excellent prognosis and pathologic response with current multimodality therapy including an individualized surgical treatment plan. Identification of a dMMR rectal cancer should trigger germline testing, followed by lifelong surveillance for both colorectal and extracolorectal malignancies. We herein provide genotype-specific outcome benchmarks for comparison with novel interventions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: de Rosa, Rodriguez-Bigas, Chang, Veerapong, Borras, Krishnan, Bednarski, Messick, Skibber, Feig, Lynch, Vilar, You Tags: Surgery, Combined Modality, Translational Oncology, Surgical Oncology Gastrointestinal Cancer Source Type: research
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward [Pediatric Oncology]
Conclusion
The EFS was uniformly poor for children with recurrent/refractory osteosarcoma in these single-arm phase II trials. We have now constructed baseline EFS outcomes that can be used as a comparison for future phase II trials for recurrent osteosarcoma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Lagmay, Krailo, Dang, Kim, Hawkins, Beaty, Widemann, Zwerdling, Bomgaars, Langevin, Grier, Weigel, Blaney, Gorlick, Janeway Tags: Osteosarcoma Pediatric Oncology Source Type: research
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy [Pediatric Oncology]
Conclusion
In children with LCH, BRAFV600E mutation was associated with high-risk features, permanent injury, and poor short-term response to chemotherapy. Further population-based studies should be undertaken to confirm our observations and to assess the impact of BRAF inhibitors for this subgroup of patients who may benefit from targeted therapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Heritier, Emile, Barkaoui, Thomas, Fraitag, Boudjemaa, Renaud, Moreau, Peuchmaur, Chassagne-Clement, Dijoud, Rigau, Moshous, Lambilliotte, Mazingue, Kebaili, Miron, Jeziorski, Plat, Aladjidi, Ferster, Pacquement, Galambrun, Brugieres, Leverger, Mansuy, Pa Tags: Histiocytic Disorders, Oncogenes Pediatric Oncology Source Type: research
Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials [Cancer Related Complications]
Conclusion
We found that in addition to drug-related factors, age and history of diabetes were independent predictors of the development of chemotherapy-induced peripheral neuropathy. Interestingly, we also observed that a history of autoimmune disease was associated with reduced odds of neuropathy. Patients with diabetic complications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other efficacious options exist. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Hershman, Till, Wright, Awad, Ramsey, Barlow, Minasian, Unger Tags: Outcomes Research Cancer Related Complications Source Type: research
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 [Urologic Oncology]
Conclusion
Cabozantinib did not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide. Cabozantinib had some activity in improving BSR, rPFS, SSEs, CTC conversions, and bone biomarkers but not PSA outcomes. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Smith, De Bono, Sternberg, Le Moulec, Oudard, De Giorgi, Krainer, Bergman, Hoelzer, De Wit, Bogemann, Saad, Cruciani, Thiery-Vuillemin, Feyerabend, Miller, Houede, Hussain, Lam, Polikoff, Stenzl, Mainwaring, Ramies, Hessel, Weitzman, Fizazi Tags: Systemic Therapy Urologic Oncology Source Type: research
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736 [Hematologic Malignancy]
Conclusion
Although 5-year PFS and OS were improved after early analysis in patients with limited-stage DLBCL receiving CHOP3RT versus CHOP8, extended survival data showed similar PFS and OS, with continuous treatment failure. The addition of rituximab (S0014) to combined-modality therapy did not mitigate the continued relapse risk, underscoring the value of prolonged clinical trial patient observation and possible unique biology of limited-stage DLBCL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Stephens, Li, LeBlanc, Puvvada, Persky, Friedberg, Smith Tags: Clinical Trials, Radiation, Chemotherapy, Combined Modality Hematologic Malignancy Source Type: research
